NHS Offers 'Revolutionary' Blood Test for Cancer in World First

NHS England has announced the introduction of 'liquid biopsy' blood tests for patients diagnosed with certain types of lung and advanced breast cancer. These tests are designed to detect fragments of tumor DNA circulating in the bloodstream, which can provide critical information about the cancer without the need for traditional tissue biopsies. This approach is expected to enable faster and less invasive diagnosis, as well as more rapid access to targeted therapies tailored to the genetic profile of the tumor. The initiative is part of NHS England's efforts to expand the use of personalized medicine in cancer care, following successful clinical trials and recommendations from health authorities. Initially, the rollout will focus on specific groups of lung and breast cancer patients, with the possibility of expanding access to more patients in the future based on the outcomes of the program. The use of liquid biopsies represents a significant advancement in cancer diagnostics and treatment, potentially improving patient outcomes and reducing the need for surgical procedures.